Scarica l'app Stockscreener
10.31
2.51%
0.04
Precedente Chiudi:
$10.35
Aprire:
$10.19
Volume 24 ore:
1,258
Relative Volume:
0.02
Capitalizzazione di mercato:
$270.30M
Reddito:
-
Utile/perdita netta:
$-28.87M
Rapporto P/E:
-8.0296
EPS:
-1.284
Flusso di cassa netto:
$-16.01M
1 W Prestazione:
-1.94%
1M Prestazione:
+13.48%
6M Prestazione:
+66.67%
1 anno Prestazione:
+2.75%
Intervallo 1D:
$10.19
$10.19
Intervallo di 1 settimana:
$10.00
$11.40
Portata 52W:
$5.55
$13.34
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Nome
Nuvectis Pharma Inc
Settore
Industria
Telefono
360-837-7232
Indirizzo
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
10.19 | 274.54M | 0 | -28.87M | -16.01M | -1.284 |
VRTX
Vertex Pharmaceuticals Inc
|
436.41 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
633.69 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.84 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.61 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.60 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-02 | Iniziato | Maxim Group | Buy |
| 2025-03-17 | Iniziato | Laidlaw | Buy |
| 2022-07-13 | Iniziato | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie
Nuvectis Pharma (NVCT) Declines 5.39% as Stock Tests Key Support LevelRelative Volume - Newser
Wall Street analysts think Nuvectis Pharma (NVCT) could surge 57%: Read this before placing a bet - MSN
Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet - sharewise.com
Nuvectis Pharma (NVCT) Surges +2.82%, Nearing $11.48 Resistance 2026-05-21Low Volatility Picks - Newser
Understanding the Setup: (NVCT) and Scalable Risk - Stock Traders Daily
NVCT Stock Price, Quote & Chart | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill
Nuvectis Pharma set to participate in key investor event at NASDAQ - Traders Union
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - The Manila Times
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor ... - Caledonian Record
Number of shareholders of Nuvectis Pharma, Inc. – NASDAQ:NVCT - TradingView
Number of shareholders of Nuvectis Pharma, Inc. – BOATS:NVCT - TradingView
TradingKey - TradingKey
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade - MSN
Nuvectis Pharma (NVCT) price target decreased by 11.71% to 16.66 - MSN
The Technical Signals Behind (NVCT) That Institutions Follow - Stock Traders Daily
What Nuvectis Pharma (NVCT) does that creates lasting value (Creeps Higher) 2026-05-08Momentum Investing - newser.com
Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Nuvectis Pharma (NVCT) - The Globe and Mail
Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth - simplywall.st
Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nuvectis Pharma | 10-Q: Q1 2026 Earnings Report - Moomoo
Nuvectis Pharma, Inc. Q1 2026: Net loss $(6.05M), EPS $(0.26) — 10-Q Summary - TradingView
Nuvectis Pharma (NASDAQ: NVCT) posts $6.1M Q1 loss with $25.1M cash - Stock Titan
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business HighlightsSEC.gov - SEC.gov
Nuvectis Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nuvectis Pharma posts first quarter 2026 financial results and business update - Traders Union
Cancer drug developer targets summer data as cash drops to $25.1M - Stock Titan
Nuvectis Pharma reports Q1 2026 loss of $6.1M, advances NXP900 cancer drug trials with data expected in summer. - Pluang
Insider Stock Buying Reaches US$2.07m On Nuvectis Pharma - Yahoo Finance
NVCT (Nuvectis Pharma) posts narrow Q4 2025 EPS miss, edging down 0.23% in muted investor reaction.Open Stock Picks - newser.com
Nuvectis Pharma Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
NVCT Forecast, Price Target & Analyst Ratings | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill
Nuvectis Pharma (NVCT) Stock: Technical Risk Signals | Q4 2025: Below ExpectationsCommunity Risk Signals - Newser
Nuvectis Pharma (NVCT) Projected to Post Earnings on Tuesday - MarketBeat
Nuvectis Pharma (NASDAQ: NVCT) details 2026 annual meeting and executive pay - Stock Titan
Precision Trading with Nuvectis Pharma Inc. (NVCT) Risk Zones - Stock Traders Daily
NVCT (Nuvectis Pharma) posts slight Q4 2025 EPS miss, yet shares edge higher on positive investor sentiment.Convertible Notes - Newser
Technical Reactions to NVCT Trends in Macro Strategies - Stock Traders Daily
Nuvectis Pharma, Inc. $NVCT Shares Acquired by Iridian Asset Management LLC CT - MarketBeat
Will Nuvectis Pharma (NVCT) Stock Recover Soon | Price at $7.65, Up 1.19%Equal Weight ETF - Newser
Trading the Move, Not the Narrative: (NVCT) Edition - Stock Traders Daily
Nuvectis Pharma (NASDAQ:NVCT) Trading Down 1.7%Here's What Happened - MarketBeat
Nuvectis to present NXP900 data at cancer research meeting By Investing.com - Investing.com South Africa
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting - Investing News Network
Nuvectis Pharma Inc Azioni (NVCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nuvectis Pharma Inc Azioni (NVCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sanchez Juan | Director |
Nov 05 '25 |
Buy |
5.79 |
13,000 |
75,270 |
78,150 |
| Kaplan Matthew L. | Director |
Nov 05 '25 |
Buy |
5.84 |
11,000 |
64,240 |
124,760 |
| Mosseri Marlio Charles | 10% Owner |
Oct 27 '25 |
Buy |
6.28 |
72,836 |
457,410 |
3,136,576 |
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
| Mosseri Marlio Charles | 10% Owner |
Jun 20 '25 |
Buy |
7.99 |
5,603 |
44,768 |
2,981,806 |
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
0.98%
2.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):